Vivoryon Therapeutics NV

Research Vivoryon Therapeutics NV (VVY) on Bullrun: market cap EUR 31.10M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerVVY
• ExchangeAS
• CountryGermany
• SectorHealthcare
• IndustryBiotechnology
• CurrencyEUR
• Market capEUR 31.10M
• Financial periodFY2025
• Net income-EUR 8.85M
• Free cash flow-EUR 8.46M

Valuation Snapshot

latest market cap is EUR 31.10M.

Company Brief

Vivoryon Therapeutics develops therapies targeting glutaminyl cyclases to treat diabetic kidney disease, supported by growing evidence validating these targets.

The company is scheduled to report its full year 2025 financial results and business updates on April 23, 2026, while presenting at an upcoming investor conference.

Despite a net income increase of 57% year-over-year compared to the prior period, Vivoryon remains loss-making as reported for FY2025.

Investors should monitor the company's full year 2025 financial results and business updates when released on April 23, 2026.

Frequently asked questions

What is Vivoryon Therapeutics NV's market cap?

Vivoryon Therapeutics NV's market capitalization is EUR 31.10M.

What does Vivoryon Therapeutics NV do?

Vivoryon Therapeutics develops therapies targeting glutaminyl cyclases to treat diabetic kidney disease, supported by growing evidence validating these targets.